New antibody takes aim at Hard-to-Treat cancers
NCT ID NCT04603287
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called SI-B001, a bispecific antibody that targets two proteins (EGFR and HER3) found on many cancer cells. The study involves about 60 adults with advanced epithelial tumors that cannot be cured or have no standard treatment. The main goals are to check the drug's safety, find the right dose, and get an early look at whether it might shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SI-B001 (a bispecific antibody that targets two proteins, EGFR and HER3, on cancer cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced epithelial cancers that have not responded to standard therapies.
- What could go wrong
- This is an early Phase I trial with only 60 participants, focused mainly on safety and dosing. It is too small and early to know if the drug will be effective or have manageable side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC EPITHELIAL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510006, China
-
West China Hospital，Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China